Creating a new method to analyze genetic changes in Crohn's disease
Development of a high-throughput epigenomic mapping platform to molecularly phenotype Crohn's disease
['FUNDING_SBIR_2'] · EPICYPHER, INC. · NIH-10683287
This study is looking at how changes in genes affect people with Crohn's disease, so we can find better ways to predict how the disease will progress and how well different treatments might work for each person, ultimately helping to create more personalized care for patients.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EPICYPHER, INC. (nih funded) |
| Locations | 1 site (Research Triangle Park, UNITED STATES) |
| Trial ID | NIH-10683287 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a high-throughput platform to map epigenomic changes in patients with Crohn's disease, a chronic gastrointestinal condition. By analyzing how gene expression is regulated in different subtypes of Crohn's, the research aims to identify unique biomarkers that can predict disease progression and treatment responses. The approach involves innovative genomic mapping techniques that are more efficient and cost-effective than current methods, making it suitable for clinical applications. Patients may benefit from more personalized treatment options based on their specific disease characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Crohn's disease who are seeking more effective treatment options.
Not a fit: Patients with other gastrointestinal disorders that are not Crohn's disease may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for patients with Crohn's disease.
How similar studies have performed: Previous research has shown promise in using genomic mapping techniques to identify biomarkers in other diseases, suggesting potential success for this novel approach.
Where this research is happening
Research Triangle Park, UNITED STATES
- EPICYPHER, INC. — Research Triangle Park, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JOHNSTONE, ANDREA LYNN — EPICYPHER, INC.
- Study coordinator: JOHNSTONE, ANDREA LYNN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.